Nat Med:小鼠体内培养人类肠组织,个性化疗法新思路

2014-10-24 佚名 生物谷

随着医学的发展,人们越来越认识到个体差异在疾病治疗过程中的重要性。而个性化治疗的思想也应运而生。最近,科学家们成功将多功能干细胞分化的肠组织移植到小鼠体内培养,形成了所谓的类"器官",为个性化疗法的进一步发展奠定了基础。在这一研究中,研究人员通过加入特定的分子组合来诱导多功能干细胞特化为肠"类器官",随后将这一结构移植到小鼠的肾被膜处进行培养。实验中小鼠首先经过基因敲除使其免疫系统不会对此类"类器

随着医学的发展,人们越来越认识到个体差异在疾病治疗过程中的重要性。而个性化治疗的思想也应运而生。最近,科学家们成功将多功能干细胞分化的肠组织移植到小鼠体内培养,形成了所谓的类"器官",为个性化疗法的进一步发展奠定了基础。在这一研究中,研究人员通过加入特定的分子组合来诱导多功能干细胞特化为肠"类器官",随后将这一结构移植到小鼠的肾被膜处进行培养。实验中小鼠首先经过基因敲除使其免疫系统不会对此类"类器官"产生排斥作用。移植后,这些"类器官"就会自动分化最终形成具有完整功能的人类肠组织。

这一研究被发表在最新一期的Nature Medicine上。研究人员表示,这一结果将能够帮助研究人员在体外更好的模拟人体环境,以测试药物对于特定个体的疗效和副作用。这也为今后治疗肠道疾病乃至癌症提供了非常适宜的实验方法。

干细胞研究一直由于其广阔前景而受到生物学家的深入研究,通过利用其分化的潜力,人们可以将其应用到药物研发、器官移植等过程中。这也极大降低了由于异源物质进入人体后引起的免疫系统排斥作用。此前,已经有利用这一方法进行皮肤移植修复烧伤的报道。

原始出处

Watson CL1, Mahe MM2, Múnera J3, Howell JC4, Sundaram N2, Poling HM2, Schweitzer JI3, Vallance JE5, Mayhew CN3, Sun Y6, Grabowski G7, Finkbeiner SR8, Spence JR8, Shroyer NF9, Wells JM3, Helmrath MA1.An in vivo model of human small intestine using pluripotent stem cells.Nat Med. 2014 Oct 19

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880332, encodeId=9fca188033236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Sep 07 18:54:00 CST 2015, time=2015-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019282, encodeId=c7e8201928205, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Jul 18 11:54:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606308, encodeId=1a181606308b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Oct 26 00:54:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2015-09-07 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880332, encodeId=9fca188033236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Sep 07 18:54:00 CST 2015, time=2015-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019282, encodeId=c7e8201928205, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Jul 18 11:54:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606308, encodeId=1a181606308b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Oct 26 00:54:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2015-07-18 晓辰
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880332, encodeId=9fca188033236, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Mon Sep 07 18:54:00 CST 2015, time=2015-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019282, encodeId=c7e8201928205, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sat Jul 18 11:54:00 CST 2015, time=2015-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606308, encodeId=1a181606308b8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Oct 26 00:54:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]